Clinical Trials Logo

Clinical Trial Summary

This is an open-label, multicenter, Phase 1, ascending dose escalation study of PSB205 in subjects with advanced solid tumors. The study will be conducted in 2 parts. Part 1 of the study will be a dose escalation evaluation to determine the maximum tolerated dose (MTD) and to establish a recommended Phase 2 dose (RP2D) of PSB205. This study purpose is to describe the safety and tolerability, to assess Pharmacokinetics (PK) and immunogenicity, and to preliminarily assess the anti-tumor activity of PSB205 in subjects with solid tumors. Part 2 of the study will further evaluate the RP2D in 3 distinct tumor cohorts of approximately 12 subjects each.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03986606
Study type Interventional
Source Qilu Puget Sound Biotherapeutics (dba Sound Biologics)
Contact Cynthia Erdman
Phone 1-913-410-2815
Email ErdmanCynthia@prahs.com
Status Recruiting
Phase Phase 1
Start date July 5, 2019
Completion date July 28, 2021

See also
  Status Clinical Trial Phase
Completed NCT01156870 - First in Man Study of SAR566658 Administered in Patients With CA6-Positive and Refractory Solid Tumor Phase 1
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Completed NCT01930552 - A Phase I Study of Aflibercept Plus FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) in Chinese Patients With Advanced Solid Malignancies Phase 1
Completed NCT01657214 - Phase I, Dose Escalation of SAR125844 in Asian Solid Tumor Patients Phase 1
Active, not recruiting NCT03911388 - HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors Phase 1
Completed NCT02575781 - A Study of SAR428926 in Patients With Advanced Solid Tumors Phase 1
Completed NCT01943838 - A Study of the Safety and Pharmacokinetics of SAR245408 Tablets in Patients With Solid Tumors or Lymphoma Phase 1
Completed NCT03324113 - Evaluation of SAR408701 in Japanese Patients With Advanced Malignant Solid Tumors Phase 1
Recruiting NCT06238687 - A Study of STRO-002 in Chinese Adults With Epithelial Ovarian Cancer and Other Advanced Malignant Solid Tumors Phase 1/Phase 2
Completed NCT02435121 - A Study Assessing Efficacy and Safety of SAR125844 in NSCLC Patients With MET Amplification Phase 2
Completed NCT01985191 - A Safety and Efficacy Study of SAR405838 and Pimasertib in Cancer Patients Phase 1
Completed NCT01455532 - A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors Phase 1
Active, not recruiting NCT03491631 - Phase I Study of SHR9146 + SHR-1210 +/- Apatinib in Patients With Advanced Solid Tumors Phase 1
Recruiting NCT04067388 - iKnife REIMS Project
Completed NCT01836705 - Effect of SAR302503 on ECG Activity in Patients With Solid Tumors Phase 1
Completed NCT01140607 - Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment Phase 1
Recruiting NCT04495790 - AIMS Cancer Outcomes Study
Recruiting NCT05714553 - NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours Phase 1/Phase 2
Recruiting NCT04733469 - EMPOWER 3: Improving Palliative Care Health Literacy and Utilization N/A
Active, not recruiting NCT03845166 - A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors Phase 1